Recent Finacing
Recent Raise
HOPSTEM develops iPSC-derived cell therapies (hNPC01 for stroke), files INDs in China and the U.S., and operates a 40k sq ft GMP R&D/manufacturing center with CMC and quality systems.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Hopstem.
